Tagged with life sciences

UK Much of the new inward investment in the UK from international pharmaceutical companies is from those that wish their discovery science to be in close adjacency to the most successful basic science programmes in biomedicinein the world. The co-location of pharmaceutical discovery sciences adjacent to the best universities (AstraZeneca in Cambridge, Novo Nordisk…

Ireland Eoin Vaughan, CEO of Mercury Engineering, and Dermot Gildea, Director of Life Sciences, highlight the key priorities of their exciting new Mercury 2021 strategy, the rationale behind their transition into a sector-based company rather than a geography-based one, their commitment to continuous improvement in terms of staff capabilities and technology,…

Switzerland Vicky Levy, head of life sciences and healthcare at Deloitte Switzerland provides a fascinating insight into the life sciences sectors on both sides of the Atlantic Ocean whilst also detailing Deloitte’s aspirations and the latest innovations in Switzerland.   Having spent the majority of your life science consulting career in…

Mexico Enrique Carballido, general manager Mexico and Latin South America at Bio-Rad, showcases Bio-Rad’s offering in both diagnostics and life sciences and the crucial role of the entire industry in helping public health institutions more effectively allocate their resources based on the number of patients covered and the economical savings obtained.…

Ireland Aidan Meagher, Tax Partner & Irish Life Sciences Lead for EY Ireland, discusses EY’s extensive consulting work, including their efforts to promote entrepreneurship in Ireland, the changing landscape facing the medtech industry in the country as well as how Ireland can work to make itself an even more attractive destination…

Luxembourg Luxembourg has a young and ambitious life sciences community, which has identified four aspects of personalized medicine where the country has significant potential: digital health, neurodegenerative diseases, molecular diagnostics and immune-oncology. Thomas Dentzer, Head of the Life Sciences sector in Luxembourg, discusses the flexible and supportive atmosphere for companies and…

Ireland Barry Heavey, Head of Life Sciences at IDA Ireland, Ireland’s inward investment promotion agency, discusses IDA’s focus on acting as a catalyst for B2B collaboration in converging industries like connective health solutions and innovative drug delivery devices, their focus on advanced manufacturing, and his mission to make IDA Ireland the…

Pharma Philippe Richert, President of the newly created region Grand Est (Regions Alsace, Champagne-Ardenne and Lorraine) shares the significance of life sciences to his local economy, the industrial heritage which have made the region a leading exporter of pharmaceuticals, as well as the world-class innovation taking place there. Finally, he discusses…

Pharma Gilles Pacaud and Christophe Bourillon discuss the importance of life sciences to Rockwell Automation France, industry trends and how the company caters to them, new opportunities in serialization, and being the partner of choice to life science companies. Ten years ago, Rockwell Automation gained international renown for laying the foundation…

Pharma Lyonbiopole was established in 2005 as a cluster designed to support the local business community focused on infectious diseases and microbiology. Philippe Archinard, the Biopole’s president, traces the evolution of the cluster over the last decade while underscoring the critical importance of transparency and collaboration between government, industry and academia.…

Pharma As CEO of the newly formed government agency Business France, Muriel Pénicaud is passionate about championing French innovation and creativity, particularly in life sciences. She tells us about her organization’s key objectives, ongoing efforts to change perceptions about France’s business environment, and her ‘bilingualism’ in the worlds of business and…

Pharma Jan Pelle Mariëtte van der Velden-Roesink Jan Pelle (JP) and Mariëtte van der Velden-Roesink (MDR) of the Brabant Development Agency (BOM) explain how they strive to offer “red-carpet treatment” to foreign investors and local companies to ultimately strengthen a life sciences eco-system based on open innovation and interdisciplinarity. As an…